Figure 2
The effect of ROX plus at-VEGF/at-VEGFR on viability and VEGF expression in EC cultures. MTT assay of rat aortic following 12–48-h treatment with ROX and/or at-VEGF or at-VEGFR. (a) MTT assay determination of the viability of cells treated for 12–48 h with 1.0 μM ROX and/or at-VEGFR or 10 ng/mL at-VEGF. (b) MTT assay determination of the viability of cells treated with PBS or 0.1–50.0 μM ROX and/or 10 ng/mL at-VEGF for 24 h. (c1) ELISA of culture supernatants from EC treated with 1.0 μM ROX and/or 10 ng/mL at-VEGF/at-VEGFR. (c2) Western blotting of total cell lysates from ECs treated with 1.0 μM ROX and/or 10 ng/mL at-VEGF/at-VEGFR. β-Actin was used as the loading control. (c3) Quantitative analysis of VEGF levels in cell lysates. (c4) Western blotting of total cell lysates from ECs treated with 1.0 μM ROX and/or 50 μM YC-1. Values are the mean ± SEM of VEGF expression standardized to β-actin expression in three independent experiments. Results are the mean ± SEM of the OD value of triplicate samples relative to the PBS control and are representative of three independent experiments. *P < 0.05, **P < 0.01 relative to PBS; #P < 0.05, ##P < 0.01 relative to 1.0 μM ROX by ANOVA.
